~~<i id='E849D3C159'><strike id='E849D3C159'><tt id='E849D3C159'><pre id='E849D3C159'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：explore 2025-10-01 10:59:34 - browse：9298

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Medicare bonuses could stop drug shortages under Senate plan

focus

hotspot

focus

explore

knowledge

AdobeIllumina,thelargestmakerofDNA-sequencingtechnologyandastoriednameinthebiotechnologyindustry,nam

WSS

High breast density mammograms need follow

Dana Farber says 6 studies to be retracted and 31 corrected

To bolster infectious disease surveillance, genomics powerhouses team up

Medicaid rebukes states for mistakenly disenrolling children

Why Novartis is changing the name of its research labs

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

leisure time

Wikipedia

focus

The high cost of giving birth even with insurance

Amazon on where the company's health care bets are headed next

Anesthesiologist group: stop taking Ozempic before surgery

Dog Aging Project founders on what lies ahead after losing funding

The high cost of giving birth even with insurance

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

23andMe had bad news about my health. I wish a person had delivered it

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Duchenne breakthrough therapy leaves behind pioneering families

What causes osteoarthritis? Researchers study link to brain protein

hotspot

There's an unseen cost to disruptive road

Snackable artificial intelligence, expert AI, and the pharma industry

Update the Apgar Score to remove skin color

Trump surgeon general acknowledges mistakes during Covid

Microsoft launches AI tool for clinical documentation through Epic

Listen: Biogen's potential pivot, & Illumina's next chapter

hotspot

focus

explore

knowledge